Is Stoke Therapeutics Stock a Good Investment?
Stoke Therapeutics Investment Advice | STOK |
- Examine Stoke Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Stoke Therapeutics' leadership team and their track record. Good management can help Stoke Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Stoke Therapeutics' business and its evolving consumer preferences.
- Compare Stoke Therapeutics' performance and market position to its competitors. Analyze how Stoke Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Stoke Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Stoke Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Stoke Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Stoke Therapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Stoke Therapeutics Stock
Researching Stoke Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are owned by institutional investors. The book value of Stoke Therapeutics was at this time reported as 4.38. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Stoke Therapeutics recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. The firm had 1:9 split on the 6th of June 2019.
To determine if Stoke Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Stoke Therapeutics' research are outlined below:
| Stoke Therapeutics generated a negative expected return over the last 90 days | |
| Stoke Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 8.78 M. Net Loss for the year was (104.7 M) with profit before overhead, payroll, taxes, and interest of 12.4 M. | |
| Stoke Therapeutics currently holds about 275.63 M in cash with (81.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Stoke Therapeutics May Find a Bottom Soon, Heres Why You Should Buy the Stock Now |
Stoke Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Stoke Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Stoke Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Stoke Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Stoke Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-08-10 | 2020-06-30 | -0.35 | -0.39 | -0.04 | 11 | ||
2024-11-05 | 2024-09-30 | -0.53 | -0.4691 | 0.0609 | 11 | ||
2023-11-07 | 2023-09-30 | -0.63 | -0.55 | 0.08 | 12 | ||
2024-08-07 | 2024-06-30 | -0.56 | -0.46 | 0.1 | 17 | ||
2021-08-10 | 2021-06-30 | -0.47 | -0.6 | -0.13 | 27 | ||
2023-05-04 | 2023-03-31 | -0.7 | -0.53 | 0.17 | 24 | ||
2020-02-23 | 2019-12-31 | -0.31 | -0.09 | 0.22 | 70 | ||
2019-08-14 | 2019-06-30 | -0.96 | -1.54 | -0.58 | 60 |
Know Stoke Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Stoke Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Stoke Therapeutics backward and forwards among themselves. Stoke Therapeutics' institutional investor refers to the entity that pools money to purchase Stoke Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-09-30 | 1.3 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 870.8 K | Granahan Investment Management Inc.. | 2024-09-30 | 645 K | Mpm Oncology Impact Management Lp | 2024-09-30 | 479.5 K | Amvescap Plc. | 2024-06-30 | 437.1 K | Cormorant Asset Management, Llc | 2024-09-30 | 427.2 K | Northern Trust Corp | 2024-09-30 | 339.2 K | Fmr Inc | 2024-09-30 | 322.9 K | Skorpios Trust | 2024-09-30 | 8.9 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 7 M |
Stoke Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 605.41 M.Market Cap |
|
Stoke Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.58) | (0.55) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.66) | (0.62) |
Determining Stoke Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Stoke Therapeutics is a good buy. For example, gross profit margin measures Stoke Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Stoke Therapeutics' profitability and make more informed investment decisions.
Evaluate Stoke Therapeutics' management efficiency
Stoke Therapeutics has return on total asset (ROA) of (0.275) % which means that it has lost $0.275 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5206) %, meaning that it created substantial loss on money invested by shareholders. Stoke Therapeutics' management efficiency ratios could be used to measure how well Stoke Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.48. Return On Capital Employed is expected to rise to -0.55 this year. At this time, Stoke Therapeutics' Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 5.1 M this year, although the value of Total Current Liabilities will most likely fall to about 15.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.63 | 4.54 | |
| Tangible Book Value Per Share | 3.63 | 4.54 | |
| Enterprise Value Over EBITDA | (0.42) | (0.44) | |
| Price Book Value Ratio | 1.45 | 1.52 | |
| Enterprise Value Multiple | (0.42) | (0.44) | |
| Price Fair Value | 1.45 | 1.52 | |
| Enterprise Value | 46.8 M | 44.5 M |
The management team at Stoke Therapeutics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 0.948 |
Basic technical analysis of Stoke Stock
As of the 24th of November, Stoke Therapeutics has the Variance of 13.18, risk adjusted performance of (0.04), and Coefficient Of Variation of (1,702). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stoke Therapeutics, as well as the relationship between them.Stoke Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Stoke Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Stoke Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Stoke Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stoke Therapeutics' Outstanding Corporate Bonds
Stoke Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Stoke Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Stoke bonds can be classified according to their maturity, which is the date when Stoke Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Stoke Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Stoke Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 2.63 | |||
| Coefficient Of Variation | (1,702) | |||
| Standard Deviation | 3.63 | |||
| Variance | 13.18 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 21.35 | |||
| Value At Risk | (6.99) | |||
| Potential Upside | 4.68 | |||
| Skewness | (0.74) | |||
| Kurtosis | 2.37 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.16) | |||
| Mean Deviation | 2.63 | |||
| Coefficient Of Variation | (1,702) | |||
| Standard Deviation | 3.63 | |||
| Variance | 13.18 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.17) | |||
| Maximum Drawdown | 21.35 | |||
| Value At Risk | (6.99) | |||
| Potential Upside | 4.68 | |||
| Skewness | (0.74) | |||
| Kurtosis | 2.37 |
Consider Stoke Therapeutics' intraday indicators
Stoke Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Stoke Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Stoke Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
ASR | 9th of October 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Stoke Stock media impact
Far too much social signal, news, headlines, and media speculation about Stoke Therapeutics that are available to investors today. That information is available publicly through Stoke media outlets and privately through word of mouth or via Stoke internal channels. However, regardless of the origin, that massive amount of Stoke data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Stoke Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Stoke Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Stoke Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Stoke Therapeutics alpha.
Stoke Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Stoke Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Stoke Therapeutics Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Jonathan JD | Corporate Counsel | Profile | |
| Shamim MS | Senior Officer | Profile | |
| FACC MD | Chief Officer | Profile | |
| Joan Wood | Chief Officer | Profile | |
| Dawn Kalmar | Chief Officer | Profile | |
| Huw Nash | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Stoke Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.